Personalized targeted therapy in advanced non-small cell lung cancer

Cleveland Clinic Journal of Medicine

Volumn 79, Issue ELECTRONICSUPPL.1, 2012, Pages 56-60

  Patrick, C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; MUTATION; ONCOGENE; PERSONALIZED MEDICINE; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; ONCOGENES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84904602272     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79.s2.12     Document Type: Article

References (25)

1. Weinstein IB, Joe AK Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Prac Oncol 2006; 3:448-457.
2. Sharma SV, Haber DA, Settleman J Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Rev Cancer 2010; 10:241-253.
3. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-smallcell lung cancer-is it becoming a reality [published correction appears in Nat Rev Clin Oncol 2011; 8:384]? Nat Rev Clin Oncol 2010; 7:401-414.
4. Schiller JH, Harrington D, Belani CP, et al Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
5. Sandler A, Gray R, Perry MC, et al Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550.
6. Fukuoka M, Yano S, Giaccone G, et al Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [published corrections appears in J Clin Oncol 2004; 22:4811[. J Clin Oncol 2003; 21:2237-2246.
7. Thatcher N, Chang A, Parikh P, et al Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537.
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
9. Ding L, Getz G, Wheeler DA, et al Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:1069-1075.
10. Harris TJR, McCormick F The molecular pathology of cancer. Nat Rev Clin Oncol 2010; 7:251-265.
11. Mok TS, Wu Y-L, Thongprasert S, et al Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957.
12. Shepherd FA Molecular selection trumps clinical selection. J Clin Oncol 2011; 29:2843-2844.
13. Keedy VL, Temin S, Somerfield MR, et al American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29:2121-2127.
14. Von Pawel J, Park K, Pereira JR, et al. Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX) [ASCO abstract 7109]. J Clin Oncol 2006; 24(SUPPL).
15. Soda M, Choi YL, Enomoto M, et al Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448:561-567.
16. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010; 46:1773-178 0.
17. Kwak EL, Bang Y-J, Camidge DR, et al Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
18. Choi YL, Soda M, Yamashits Y, et al EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363:1734-1739.
19. Birchmeier C, Birchmeier W, Gherardi E, VandeWoude GF MET, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4:915-925.
20. Feng Y, Ma PC Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer. Cancer Discovery 2011; 1:550-554.
21. Feng Y, Thiagarajan PS, Ma PC MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2012; 7:459-467.
22. Sequist LV, Akerley WL, Brugger W, et al. Final results from ARQ 197-209: a global randomized placebo-controlled trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC) [ESMO abstract 3630]. Ann Oncol 2010; 21 (suppl 8):viii122.
23. Sharma SV, Settleman J Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21:3214-3231.
24. Fan W, Tang Z, Yin L, et al. MET-independent lung cancer cells evading EGRF kinase inhibitors are therapeutically susceptible to BH3 mimetic agents [published online ahead of print May 9, 2011]. Cancer Res 2011; 71:4494-4505. doi:10.1158/0008-5472.CAN-10-2668
25. Kris MG, Natale RB, Herbst RS, et al Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.